Company Bigtincan Holdings Limited

Equities

BTH

AU000000BTH6

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Bigtincan Holdings Limited

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:42 2024-05-02 am EDT			5-day change	1st Jan Change
0.15 ^AUD	+3.45%		-3.23%	-25.00%

Apr. 11	Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19%	MT
Mar. 18	Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index	CI

Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.

Number of employees: 495

AUD in Million	2022	Weight	2023	Weight	Delta
Subscription and Support Services 93.8 %	102	94.4 %	115	93.8 %	+12.54%
Professional and Contract Services 6.2 %	6	5.6 %	8	6.2 %	+26.07%

AUD in Million	2022	Weight	2023	Weight	Delta
United States 83.3 %	94	86.6 %	102	83.3 %	+8.99%
Rest of the World 12.1 %	10	9.5 %	15	12.1 %	+43.84%
Australia 4.6 %	4	3.9 %	6	4.6 %	+34.36%

Managers	Title	Age	Since
David Keane FOU	Founder	-	10-12-31
Patrick Welch PSD	President	-	11-12-31
Vivian Stewart COO	Chief Operating Officer	-	14-10-31
Mark Ohlsson IRC	Investor Relations Contact	-	11-12-31
Stefan Teulon PRN	Corporate Officer/Principal	-	-
Cyril Desouza AUD	Comptroller/Controller/Auditor	-	-
Kent Erickson PRN	Corporate Officer/Principal	-	18-04-04

Members of the board	Title	Age	Since
Inese Kingsmill BRD	Director/Board Member	-	21-10-05
Wayne Stevenson BRD	Director/Board Member	-	16-09-27
David Keane FOU	Founder	-	10-12-31
Thomas Amos CHM	Chairman	-	16-09-27

Name	Equities	%	Valuation
Regal Funds Management Pty Ltd. 12.71 %	78,354,792	12.71 %	8 M $
SQN Investors LP 12.16 %	74,940,121	12.16 %	8 M $
MA Investment Management Pty Ltd. 4.473 %	27,563,168	4.473 %	3 M $
David Keane 3.852 %	23,740,992	3.852 %	2 M $
Lai Sun Keane 2.307 %	14,217,541	2.307 %	1 M $
Estate of Cohen Geoffrey 1.145 %	7,053,875	1.145 %	713 288 $
Aotearoa Investment Co. Pty Ltd. 0.7838 %	4,830,014	0.7838 %	488 411 $
SBCVC Fund IV Pte Ltd. 0.5619 %	3,462,784	0.5619 %	350 157 $
Southern Cross Iif Trusco Pty Ltd. 0.5210 %	3,210,380	0.5210 %	324 634 $
Isle of Wight Pty Ltd. 0.3822 %	2,355,552	0.3822 %	238 193 $

BigTinCan Holdings Ltd.

338 Pitt Street Level 6

2000, Sydney

http://www.bigtincan.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.145 AUD

Average target price

0.39 AUD

Spread / Average Target

+168.97%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIGTINCAN HOLDINGS LIMITED	-25.00%	58.04M
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+46.73%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research